Neurology
Page 2 • 9 itemsGain critical insights into global neurology drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.
CervoMed's Neflamapimod Shows Brain Volume Improvements in Dementia with Lewy Bodies at AAN 2026
CervoMed reports neflamapimod increased basal forebrain volume in DLB patients, suggesting potential disease reversal in early neurodegenerative stages.
Leerink Partners Initiates Medincell Coverage with Outperform Rating Following UZEDY Risperidone LAI FDA Approvals
Leerink Partners initiates Medincell coverage with Outperform rating as UZEDY risperidone LAI gains FDA approval for schizophrenia and bipolar disorder treatment.
AskBio's Ametefgene Parvec Enters Phase II Trial for Parkinson's Disease Gene Therapy
AskBio advances Ametefgene parvec (AB-1005) to Phase II trials for Parkinson's disease using commercial-scale manufacturing at Viralgen facility.
EMA Recommends Adstiladrin Gene Therapy for Bladder Cancer Treatment in March 2026
EMA's CHMP recommends conditional approval for Adstiladrin gene therapy to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
EMA Approves Hanmi Pharmaceutical's HMPL-523 Herbal Medicine for Alzheimer's Disease Treatment
European Medicines Agency grants marketing authorization for HMPL-523, marking first herbal medicine approval for mild to moderate Alzheimer's disease treatment.
AB Science Secures €25 Million Clinical Trial Insurance for Masitinib ALS Phase III Study
AB Science obtains €25M clinical trial insurance for masitinib ALS Phase III study while implementing temporary European trial halt amid regulatory review.
IMVT-1402 and 7 Other Late-Stage Drugs Transform Generalized Myasthenia Gravis Treatment Pipeline in 2026
Eight promising late-stage drugs including IMVT-1402 from Immunovant signal breakthrough era for generalized myasthenia gravis patients with novel mechanisms.
Medicenna's Bizaxofusp Shows Promise in Brain Cancer Trials Ahead of 2026 Investor Conference
Medicenna's bizaxofusp demonstrates clinical progress in glioblastoma trials with FDA FastTrack status, positioning for major investor presentation in 2026.
Grace Therapeutics GTx-104 Phase 3 STRIVE-ON Trial Results Accepted for AAN 2026 Presentation
Grace Therapeutics announces STRIVE-ON Phase 3 safety trial results for GTx-104 injectable nimodipine accepted for AAN 2026 presentation.